Abstract
CRISPR biotechnologies, primarily used as a tool for precision gene editing, have an emerging potential for antiviral diagnostics, therapeutics, and prophylactics. However, despite significant differences in the goals and desired outcomes between gene editing and antiviral applications, the methods for designing the guide RNAs (gRNAs) that determine the polynucleotide sequence a CRISPR effector will degrade remain the same for both: gene editing requires extreme “specificity” by permitting CRISPR activity only at a single target and not any other similar sequences, while antiviral applications require tolerance to clinical polymorphisms and suppression of viral mutational escape, which is often accomplished by targeting multiple viral sequences at once.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
